Table 1. FcγRIIa and FcγRIIIa alleles and their associations in HIV infection, vaccination and disease progression.
NE represents allele combinations that were not evaluated.
| Observation | HH | HR | RR | VV | VF | FF | Notes | Ref. |
|---|---|---|---|---|---|---|---|---|
| Decline in proportion of subjects with CD4+ cells >=200/mm2 over time | − | − | + | − | − | − | RR faster decline | (67) |
| Decline in proportion of subjects without AIDS over time | − | − | + | − | − | − | RR faster decline | |
| Risk of P. jiroveci pneumonia as an AIDS-defining illness | + | − | − | − | − | − | HH higher risk, R lower risk | |
| HIV viral RNA/ml setpoint at ~18 mo | − | − | − | NE | NE | NE | No association | |
| Monocyte internalization of HIV immune complexes | +++ | ++ | + | NE | NE | NE | HH highest internalization | |
| Risk of Kaposi's sarcoma | − | − | − | + | − | − | VV higher risk | |
| Risk of perinatal HIV-1 transmission based on infant allotype | + | − | (+) | NE | NE | NE | HH higher risk, RR lower risk | (68) |
| Risk of perinatal HIV-1 transmission based on maternal allotype | − | − | − | NE | NE | NE | No association | |
| Lower HIV replication post vaccination | + | + | − | NE | NE | NE | HH or H/R smaller increase | (69) |
| Increased risk of infection | − | − | − | + | + | − | V increased risk | (70) |
| Risk of disease progression | − | − | + | + | − | + | VV and RR/FF increased risk | |
| Rate of infection for placebo recipients (Vax004) | − | − | − | − | − | − | No association | (71) |
| Rate of infection for low risk vaccine recipients (Vax004) | − | − | − | + | − | − | VV increased rate | |
| Risk of infection for vaccine trial participants (Step) | − | − | − | − | − | − | No association | (72) |
| Risk of infection (RV144) | − | − | − | − | − | − | No association | (73) |